Literature DB >> 31701199

Positioning time in range in diabetes management.

Andrew Advani1.   

Abstract

Recent upswings in the use of continuous glucose monitoring (CGM) technologies have given people with diabetes and healthcare professionals unprecedented access to a range of new indicators of glucose control. Some of these metrics are useful research tools and others have been welcomed by patient groups for providing insights into the quality of glucose control not captured by conventional laboratory testing. Among the latter, time in range (TIR) is an intuitive metric that denotes the proportion of time that a person's glucose level is within a desired target range (usually 3.9-10.0 mmol/l [3.5-7.8 mmol/l in pregnancy]). For individuals choosing to use CGM technology, TIR is now often part of the expected conversation between patient and healthcare professional, and consensus recommendations have recently been produced to facilitate the adoption of standardised TIR targets. At a regulatory level, emerging evidence linking TIR to risk of complications may see TIR being more widely accepted as a valid endpoint in future clinical trials. However, given the skewed distribution of possible glucose values outside of the target range, TIR (on its own) is a poor indicator of the frequency or severity of hypoglycaemia. Here, the state-of-the-art linking TIR with complications risk in diabetes and the inverse association between TIR and HbA1c are reviewed. Moreover, the importance of including the amount and severity of time below range (TBR) in any discussions around TIR and, by inference, time above range (TAR) is discussed. This review also summarises recent guidance in setting 'time in ranges' goals for individuals with diabetes who wish to make use of these metrics. For most people with type 1 or type 2 diabetes, a TIR >70%, a TBR <3.9 mmol/l of <4%, and a TBR <3.0 mmol/l of <1% are recommended targets, with less stringent targets for older or high-risk individuals and for those under 25 years of age. As always though, glycaemic targets should be individualised and rarely is that more applicable than in the personal use of CGM and the data it provides.

Entities:  

Keywords:  CGM; Diabetes complications; HbA1c; Hyperglycaemia; Hypoglycaemia; Review; Time below range; Time in range

Mesh:

Substances:

Year:  2019        PMID: 31701199     DOI: 10.1007/s00125-019-05027-0

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  61 in total

Review 1.  Metrics Beyond Hemoglobin A1C in Diabetes Management: Time in Range, Hypoglycemia, and Other Parameters.

Authors:  Lorena Alarcon-Casas Wright; Irl B Hirsch
Journal:  Diabetes Technol Ther       Date:  2017-05       Impact factor: 6.118

2.  When HbA1c and Blood Glucose Do Not Match: How Much Is Determined by Race, by Genetics, by Differences in Mean Red Blood Cell Age?

Authors:  Robert M Cohen; Robert S Franco; Eric P Smith; John M Higgins
Journal:  J Clin Endocrinol Metab       Date:  2019-03-01       Impact factor: 5.958

3.  Glycemic goals in diabetes: trade-off between glycemic control and iatrogenic hypoglycemia.

Authors:  Philip E Cryer
Journal:  Diabetes       Date:  2014-07       Impact factor: 9.461

4.  FreeStyle Libre: contact irritation versus contact allergy.

Authors:  Olivier Aerts; Anne Herman; Magnus Bruze; An Goossens; Martin Mowitz
Journal:  Lancet       Date:  2017-10-05       Impact factor: 79.321

5.  The Relationships Between Time in Range, Hyperglycemia Metrics, and HbA1c.

Authors:  Roy W Beck; Richard M Bergenstal; Peiyao Cheng; Craig Kollman; Anders L Carlson; Mary L Johnson; David Rodbard
Journal:  J Diabetes Sci Technol       Date:  2019-01-13

6.  Translating glycated hemoglobin A1c into time spent in glucose target range: A multicenter study.

Authors:  Jonathan Petersson; Karin Åkesson; Frida Sundberg; Stefan Särnblad
Journal:  Pediatr Diabetes       Date:  2019-01-31       Impact factor: 4.866

7.  Optimizing Hybrid Closed-Loop Therapy in Adolescents and Emerging Adults Using the MiniMed 670G System.

Authors:  Laurel H Messer; Gregory P Forlenza; Jennifer L Sherr; R Paul Wadwa; Bruce A Buckingham; Stuart A Weinzimer; David M Maahs; Robert H Slover
Journal:  Diabetes Care       Date:  2018-02-14       Impact factor: 19.112

8.  Glucose Variability: Timing, Risk Analysis, and Relationship to Hypoglycemia in Diabetes.

Authors:  Boris Kovatchev; Claudio Cobelli
Journal:  Diabetes Care       Date:  2016-04       Impact factor: 19.112

9.  Changes in the glycemic profiles of women with type 1 and type 2 diabetes during pregnancy.

Authors:  Helen R Murphy; Gerry Rayman; Katherine Duffield; Karen S Lewis; Susan Kelly; Balroop Johal; Duncan Fowler; Rosemary C Temple
Journal:  Diabetes Care       Date:  2007-07-31       Impact factor: 19.112

10.  Glycaemic control in type 1 diabetes during real time continuous glucose monitoring compared with self monitoring of blood glucose: meta-analysis of randomised controlled trials using individual patient data.

Authors:  John C Pickup; Suzanne C Freeman; Alex J Sutton
Journal:  BMJ       Date:  2011-07-07
View more
  16 in total

1.  Largest Amplitude of Glycemic Excursion Calculating from Self-Monitoring Blood Glucose Predicted the Episodes of Nocturnal Asymptomatic Hypoglycemia Detecting by Continuous Glucose Monitoring in Outpatients with Type 2 Diabetes.

Authors:  Shoubi Wang; Zhenhua Tan; Ting Wu; Qingbao Shen; Peiying Huang; Liying Wang; Wei Liu; Haiqu Song; Mingzhu Lin; Xiulin Shi; Xuejun Li
Journal:  Front Endocrinol (Lausanne)       Date:  2022-04-14       Impact factor: 6.055

2.  Time in Range as a Research Outcome Measure.

Authors:  Joseph G Timmons; James G Boyle; John R Petrie
Journal:  Diabetes Spectr       Date:  2021-05-25

3.  Clinical Application of Time in Range and Other Metrics.

Authors:  Grazia Aleppo
Journal:  Diabetes Spectr       Date:  2021-05-25

4.  Novel Biochemical Markers of Glycemia to Predict Pregnancy Outcomes in Women With Type 1 Diabetes.

Authors:  Claire L Meek; Diana Tundidor; Denice S Feig; Jennifer M Yamamoto; Eleanor M Scott; Diane D Ma; Jose A Halperin; Helen R Murphy; Rosa Corcoy
Journal:  Diabetes Care       Date:  2021-01-25       Impact factor: 19.112

Review 5.  Individualizing Time-in-Range Goals in Management of Diabetes Mellitus and Role of Insulin: Clinical Insights From a Multinational Panel.

Authors:  Sanjay Kalra; Shehla Shaikh; Gagan Priya; Manas P Baruah; Abhyudaya Verma; Ashok K Das; Mona Shah; Sambit Das; Deepak Khandelwal; Debmalya Sanyal; Sujoy Ghosh; Banshi Saboo; Ganapathi Bantwal; Usha Ayyagari; Daphne Gardner; Cecilia Jimeno; Nancy E Barbary; Khadijah A Hafidh; Jyoti Bhattarai; Tania T Minulj; Hendra Zufry; Uditha Bulugahapitiya; Moosa Murad; Alexander Tan; Selim Shahjada; Mijinyawa B Bello; Prasad Katulanda; Gracjan Podgorski; Wajeeha I AbuHelaiqa; Rima Tan; Ali Latheef; Sedeshan Govender; Samir H Assaad-Khalil; Cecilia Kootin-Sanwu; Ansumali Joshi; Faruque Pathan; Diana A Nkansah
Journal:  Diabetes Ther       Date:  2020-12-26       Impact factor: 2.945

Review 6.  Time-in-range as a target in type 2 diabetes: An urgent need.

Authors:  Banshi Saboo; Jothydev Kesavadev; Arun Shankar; Meera B Krishna; Shruti Sheth; Vidisha Patel; Gopika Krishnan
Journal:  Heliyon       Date:  2021-01-15

7.  A synthetic BRET-based optogenetic device for pulsatile transgene expression enabling glucose homeostasis in mice.

Authors:  Ting Li; Xianjun Chen; Yajie Qian; Jiawei Shao; Xie Li; Shuning Liu; Linyong Zhu; Yuzheng Zhao; Haifeng Ye; Yi Yang
Journal:  Nat Commun       Date:  2021-01-27       Impact factor: 14.919

8.  Glycemic deviation index: a novel method of integrating glycemic numerical value and variability.

Authors:  Yizhou Zou; Wanli Wang; Dongmei Zheng; Xu Hou
Journal:  BMC Endocr Disord       Date:  2021-03-19       Impact factor: 2.763

9.  Improved time in range and postprandial hyperglycemia with canagliflozin in combination with teneligliptin: Secondary analyses of the CALMER study.

Authors:  Kyu Yong Cho; Hiroshi Nomoto; Akinobu Nakamura; Shinichiro Kawata; Hajime Sugawara; Jun Takeuchi; So Nagai; Kazuno Omori; Kazuhisa Tsuchida; Aika Miya; Ikumi Shigesawa; Kenichi Tsuchida; Shingo Yanagiya; Hiraku Kameda; Hiroki Yokoyama; Shinji Taneda; Yoshio Kurihara; Shin Aoki; Naoki Nishimoto; Tatsuya Atsumi; Hideaki Miyoshi
Journal:  J Diabetes Investig       Date:  2021-02-05       Impact factor: 4.232

10.  Diabetes Technology Meeting 2020.

Authors:  Trisha Shang; Jennifer Y Zhang; B Wayne Bequette; Jennifer K Raymond; Gerard Coté; Jennifer L Sherr; Jessica Castle; John Pickup; Yarmela Pavlovic; Juan Espinoza; Laurel H Messer; Tim Heise; Carlos E Mendez; Sarah Kim; Barry H Ginsberg; Umesh Masharani; Rodolfo J Galindo; David C Klonoff
Journal:  J Diabetes Sci Technol       Date:  2021-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.